Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression

Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. There has been a lot of attention to applying these drugs for solid tumor treatment. Recent preclinical study has signified the effectiveness on cell proliferation inhibition in lung adenocarcinoma treated...

Full description

Saved in:
Bibliographic Details
Published inJournal of Zhejiang University. B. Science Vol. 21; no. 1; pp. 64 - 76
Main Authors Yang, Fang, Liu, Wang-wang, Chen, Hui, Zhu, Jia, Huang, Ai-hua, Zhou, Fei, Gan, Yi, Zhang, Yan-hua, Ma, Li
Format Journal Article
LanguageEnglish
Published Hangzhou Zhejiang University Press 2020
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. There has been a lot of attention to applying these drugs for solid tumor treatment. Recent preclinical study has signified the effectiveness on cell proliferation inhibition in lung adenocarcinoma treated by carfilzomib (CFZ), a second generation proteasome inhibitor. However, no insight has been gained regarding the mechanism. In this study, we have systematically investigated the CFZ functions in cell proliferation and growth, cell cycle arrest, and apoptosis in lung adenocarcinoma cells. Flow cytometry experiments showed that CFZ significantly induced G2/M cell cycle arrest and apoptosis in lung adenocarcinoma. MTS and colony formation assays revealed that CFZ substantially inhibited survival of lung adenocarcinoma cells. All results were consistently correlated to the upregulation expression of Gadd45a , which is an important gene in modulating cell cycle arrest and apoptosis in response to physiologic and environmental stresses. Here, upregulation of Gadd45a expression was observed after CFZ treatment. Knocking down Gadd45a expression suppressed G2/M arrest and apoptosis in CFZ-treated cells, and reduced cytotoxicity of this drug. The protein expression analysis has further identified that the AKT/FOXO3a pathway is involved in Gadd45a upregulation after CFZ treatment. These findings unveil a novel mechanism of proteasome inhibitor in anti-solid tumor activity, and shed light on novel preferable therapeutic strategy for lung adenocarcinoma. We believe that Gadd45a expression can be a highly promising candidate predictor in evaluating the efficacy of proteasome inhibitors in solid tumor therapy.
AbstractList Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. There has been a lot of attention to applying these drugs for solid tumor treatment. Recent preclinical study has signified the effectiveness on cell proliferation inhibition in lung adenocarcinoma treated by carfilzomib (CFZ), a second generation proteasome inhibitor. However, no insight has been gained regarding the mechanism. In this study, we have systematically investigated the CFZ functions in cell proliferation and growth, cell cycle arrest, and apoptosis in lung adenocarcinoma cells. Flow cytometry experiments showed that CFZ significantly induced G2/M cell cycle arrest and apoptosis in lung adenocarcinoma. MTS and colony formation assays revealed that CFZ substantially inhibited survival of lung adenocarcinoma cells. All results were consistently correlated to the upregulation expression of Gadd45a , which is an important gene in modulating cell cycle arrest and apoptosis in response to physiologic and environmental stresses. Here, upregulation of Gadd45a expression was observed after CFZ treatment. Knocking down Gadd45a expression suppressed G2/M arrest and apoptosis in CFZ-treated cells, and reduced cytotoxicity of this drug. The protein expression analysis has further identified that the AKT/FOXO3a pathway is involved in Gadd45a upregulation after CFZ treatment. These findings unveil a novel mechanism of proteasome inhibitor in anti-solid tumor activity, and shed light on novel preferable therapeutic strategy for lung adenocarcinoma. We believe that Gadd45a expression can be a highly promising candidate predictor in evaluating the efficacy of proteasome inhibitors in solid tumor therapy.
Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. There has been a lot of attention to applying these drugs for solid tumor treatment. Recent preclinical study has signified the effectiveness on cell proliferation inhibition in lung adenocarcinoma treated by carfilzomib (CFZ), a second generation proteasome inhibitor. However, no insight has been gained regarding the mechanism. In this study, we have systematically investigated the CFZ functions in cell proliferation and growth, cell cycle arrest, and apoptosis in lung adenocarcinoma cells. Flow cytometry experiments showed that CFZ significantly induced G2/M cell cycle arrest and apoptosis in lung adenocarcinoma. MTS and colony formation assays revealed that CFZ substantially inhibited survival of lung adenocarcinoma cells. All results were consistently correlated to the upregulation expression of Gadd45a, which is an important gene in modulating cell cycle arrest and apoptosis in response to physiologic and environmental stresses. Here, upregulation of Gadd45a expression was observed after CFZ treatment. Knocking down Gadd45a expression suppressed G2/M arrest and apoptosis in CFZ-treated cells, and reduced cytotoxicity of this drug. The protein expression analysis has further identified that the AKT/FOXO3a pathway is involved in Gadd45a upregulation after CFZ treatment. These findings unveil a novel mechanism of proteasome inhibitor in anti-solid tumor activity, and shed light on novel preferable therapeutic strategy for lung adenocarcinoma. We believe that Gadd45a expression can be a highly promising candidate predictor in evaluating the efficacy of proteasome inhibitors in solid tumor therapy.
Author Chen, Hui
Zhu, Jia
Ma, Li
Liu, Wang-wang
Yang, Fang
Gan, Yi
Huang, Ai-hua
Zhou, Fei
Zhang, Yan-hua
AuthorAffiliation 3 Department of Neurosurgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
1 Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
2 Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
AuthorAffiliation_xml – name: 3 Department of Neurosurgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
– name: 1 Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
– name: 2 Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
Author_xml – sequence: 1
  givenname: Fang
  orcidid: 0000-0003-0688-5690
  surname: Yang
  fullname: Yang, Fang
  email: xiaoyangpumc@zju.edu.cn
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 2
  givenname: Wang-wang
  surname: Liu
  fullname: Liu, Wang-wang
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 3
  givenname: Hui
  surname: Chen
  fullname: Chen, Hui
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 4
  givenname: Jia
  surname: Zhu
  fullname: Zhu, Jia
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 5
  givenname: Ai-hua
  surname: Huang
  fullname: Huang, Ai-hua
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 6
  givenname: Fei
  surname: Zhou
  fullname: Zhou, Fei
  organization: Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 7
  givenname: Yi
  surname: Gan
  fullname: Gan, Yi
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 8
  givenname: Yan-hua
  surname: Zhang
  fullname: Zhang, Yan-hua
  organization: Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 9
  givenname: Li
  surname: Ma
  fullname: Ma, Li
  organization: Department of Neurosurgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31898443$$D View this record in MEDLINE/PubMed
BookMark eNptkctv1DAQxi3Uij7gyBVF4sIlix2_L0h0BQWpUi_tEVkTx8l6ldiLnRToX49X25aHOM1ovp--mdF3ho5CDA6hVwSviKDk3fZ-yasLojHmnDxDp0SJpiZS0aPSC0lrwhU5QWc5bzFmDEvxHJ1QorRijJ6ir2tIvR_v4-TbyoeNb_2cq3njqiHF7_Omin01LmGooHMhWkjWhzhBdeehWnbJDcsIs49hz11C1zEOlftRhJzL9AU67mHM7uVDPUe3nz7erD_XV9eXX9YfrmrLOJtrKxonueMdl6pzwKmmpBd9K1qOOwlAqNBEUkKt5I0jomXQWGoFONpo1QM9R-8PvrulnVxnXZgTjGaX_ATpp4ngzd9K8BszxDsjtGBa82Lw9sEgxW-Ly7OZfLZuHCG4uGTTUEoFlpqqgr75B93GJYXyXqEYbRQnCheqPlA2xZyT65-OIdjsgzP74MxjcIV__ecHT_RjUgVYHYBcpDC49Hvt_x1_Ae7spy4
CitedBy_id crossref_primary_10_1016_j_bbrep_2022_101357
crossref_primary_10_1016_j_bcp_2023_115939
crossref_primary_10_1186_s13046_021_02057_8
crossref_primary_10_3724_abbs_2024040
crossref_primary_10_1631_jzus_B2100170
crossref_primary_10_2139_ssrn_4173657
crossref_primary_10_1016_j_biopha_2024_116833
Cites_doi 10.1007/s10495-008-0282-x
10.1038/sj.onc.1207301
10.1074/jbc.M000284200
10.1128/MCB.25.11.4488-4500.2005
10.1126/science.7973727
10.1126/science.1068712
10.1038/13802
10.1002/jcp.26588
10.1186/s13046-014-0111-8
10.1038/sj.emboj.7600279
10.1093/nar/gkt223
10.1038/sj.onc.1210469
10.1016/S0092-8674(00)81619-0
10.1038/sj.onc.1202667
10.1016/j.lungcan.2009.05.009
10.1186/s12943-018-0856-3
10.1186/1750-2187-3-15
10.1016/j.trsl.2018.03.002
10.1038/sj.onc.1206034
10.1631/jzus.B1700148
10.1182/blood-2012-05-425934
10.1074/jbc.M112.418335
10.1007/s00432-015-2047-6
10.3322/caac.21442
10.1038/s41419-018-0452-x
10.1158/1078-0432.CCR-07-2218
10.1631/jzus.B1800211
10.1074/jbc.M213069200
10.1074/jbc.M212835200
10.1124/jpet.115.226993
10.1038/nrclinonc.2016.206
10.3322/caac.21349
10.1016/j.lungcan.2010.06.005
10.1007/s12253-017-0255-x
10.1016/j.critrevonc.2016.01.024
10.1007/978-1-4614-8289-5_1
ContentType Journal Article
Copyright Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019
2019© Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019
Copyright © Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2020 2020
Copyright_xml – notice: Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019
– notice: 2019© Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2019
– notice: Copyright © Zhejiang University and Springer-Verlag GmbH Germany, part of Springer Nature 2020 2020
DBID NPM
AAYXX
CITATION
7QO
7QP
7TK
8FD
FR3
K9.
P64
7X8
5PM
DOI 10.1631/jzus.B1900551
DatabaseName PubMed
CrossRef
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
Biotechnology Research Abstracts
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList

PubMed
Biotechnology Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitle_FL Carfilzomib 通过上调 Gadd45a 表达抑制肺腺癌细胞生长
EISSN 1862-1783
EndPage 76
ExternalDocumentID 10_1631_jzus_B1900551
31898443
Genre Journal Article
GroupedDBID -56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
188
1N0
29L
29~
2B.
2C.
2J2
2JN
2JY
2KG
2KM
2LR
2WC
30V
3V.
4.4
406
408
40D
40E
53G
5GY
5VR
5VS
67N
6NX
7X2
7X7
7XC
88E
8AO
8CJ
8FE
8FG
8FH
8FI
8FJ
8UJ
92E
92I
92Q
93N
95-
95.
95~
96X
AAAVM
AABHQ
AAFGU
AAHNG
AAIAL
AAJKR
AAKDD
AANXM
AANZL
AARHV
AARTL
AATNV
AAYFA
AAYIU
AAYQN
ABBBX
ABDZT
ABECU
ABFGW
ABFTV
ABHLI
ABJCF
ABJNI
ABJOX
ABKAS
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABUWG
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACPRK
ACSNA
ACTTH
ACVWB
ACWMK
ADHHG
ADHIR
ADINQ
ADKPE
ADMDM
ADOXG
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFTE
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AESTI
AETLH
AEVLU
AEVTX
AEXYK
AFKRA
AFLOW
AFNRJ
AFRAH
AFUIB
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGJBK
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYQR
AOCGG
ARAPS
ARMRJ
ASPBG
ATCPS
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKSAR
BPHCQ
BVXVI
CAG
CCEZO
CCPQU
CEKLB
CHBEP
COF
CS3
CSCUP
CW9
D1I
D1J
D1K
DDRTE
DIK
DNIVK
DPUIP
DU5
E3Z
EBLON
EBS
EIOEI
EJD
ESBYG
F5P
FA0
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
HCIFZ
HF~
HG6
HH5
HLICF
HMCUK
HMJXF
HRMNR
HVGLF
HYE
HZ~
IHE
IKXTQ
IWAJR
IXD
I~X
I~Z
J-C
JBSCW
JZLTJ
K6-
KB.
KDC
KOV
L6V
LK5
LK8
LLZTM
M0K
M1P
M4Y
M7P
M7R
M7S
MA-
N2Q
NB0
NPVJJ
NQJWS
NU0
O9-
O9J
OK1
OVD
P62
PATMY
PCBAR
PDBOC
PF0
PQQKQ
PROAC
PSQYO
PT4
PTHSS
PYCSY
Q2X
QOR
QOS
R89
R9I
ROL
RPM
RPX
RSV
S16
S1Z
S27
S3A
S3B
SAP
SBL
SCL
SDH
SHX
SISQX
SJN
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
SZN
T13
TCJ
TEORI
TGP
TR2
TSG
TUC
U2A
U9L
UG4
UGNYK
UKHRP
UNUBA
UOJIU
UTJUX
UZ3
UZ4
UZ5
UZXMN
VC2
VFIZW
W23
W48
WK8
WOQ
YLTOR
ZMTXR
ZOVNA
~A9
AAJBT
AASML
AAXDM
ABAKF
ACAOD
ACDTI
ACZOJ
AEFQL
AEMSY
AGQEE
AGRTI
AIGIU
NPM
-SA
-S~
AACDK
AAHBH
AAYXX
ALIPV
CAJEA
CITATION
H13
Q--
U1G
U5K
7QO
7QP
7TK
8FD
FR3
K9.
P64
7X8
5PM
ID FETCH-LOGICAL-c454t-c62e75e5d578dea53931f6fb6b50d7aa136917313c752e16b4a2c3c6ae3298fa3
IEDL.DBID RPM
ISSN 1673-1581
IngestDate Tue Sep 17 21:23:32 EDT 2024
Fri Aug 16 23:49:35 EDT 2024
Fri Sep 13 09:23:24 EDT 2024
Thu Sep 12 16:47:36 EDT 2024
Thu May 23 23:58:08 EDT 2024
Sat Dec 16 12:02:58 EST 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords R734.2
Carfilzomib
Cell cycle arrest
细胞周期阻滞
Gadd45a
Lung adenocarcinoma
卡非佐米 (Carfilzomib)
凋亡
Apoptosis
肺腺癌
Carfilzomib; Lung adenocarcinoma; Gadd45a; Cell cycle arrest; Apoptosis
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c454t-c62e75e5d578dea53931f6fb6b50d7aa136917313c752e16b4a2c3c6ae3298fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Corresponding Author
ORCID 0000-0003-0688-5690
OpenAccessLink https://europepmc.org/articles/pmc6964995?pdf=render
PMID 31898443
PQID 2343285180
PQPubID 326286
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6964995
proquest_miscellaneous_2333607938
proquest_journals_2343285180
crossref_primary_10_1631_jzus_B1900551
pubmed_primary_31898443
springer_journals_10_1631_jzus_B1900551
PublicationCentury 2000
PublicationDate 1-2020
2020 Jan.
2020-01-00
20200101
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – year: 2020
  text: 1-2020
PublicationDecade 2020
PublicationPlace Hangzhou
PublicationPlace_xml – name: Hangzhou
– name: China
PublicationSubtitle Biomedicine & Biotechnology
PublicationTitle Journal of Zhejiang University. B. Science
PublicationTitleAbbrev J. Zhejiang Univ. Sci. B
PublicationTitleAlternate J Zhejiang Univ Sci B
PublicationYear 2020
Publisher Zhejiang University Press
Springer Nature B.V
Publisher_xml – name: Zhejiang University Press
– name: Springer Nature B.V
References Orlowski, Kuhn (CR22) 2008; 14
Takekawa, Saito (CR30) 1998; 95
Yao, Fu, Du (CR36) 2018; 19
Chung, Yi, Jung (CR4) 2003; 278
Ji, Liu, Tong (CR11) 2007; 26
Bouchard, Marquardt, Brás (CR3) 2004; 23
Gao, Li, Dong (CR6) 2013; 41
Siegel, Martin, Wang (CR27) 2012; 120
Tong, Ji, Jin (CR31) 2005; 25
Morgillo, D’Aiuto, Troiani (CR21) 2011; 71
van der Wekken, Saber, Hiltermann (CR33) 2016; 100
Liu, Tian, Xiong (CR17) 2018; 233
Hollander, Kovalsky, Salvador (CR10) 2001; 61
Baker, Hanke, Sands (CR2) 2014; 33
da Silva, Filoni, Salvadori (CR5) 2018; 24
Manasanch, Orlowski (CR19) 2017; 14
Miller, Siegel, Lin (CR20) 2016; 66
Jin, Antinore, Lung (CR12) 2000; 275
Yang, Zhang, Li (CR35) 2013; 288
Siegel, Miller, Jemal (CR28) 2018; 68
Yang, Yang, Wood (CR34) 2009; 14
Hildesheim, Belova, Tyner (CR8) 2004; 23
Smith, Chen, Zhan (CR29) 1994; 266
Li, Wei, Zhou (CR14) 2018; 9
Hanke, Garland, Baker (CR7) 2016; 142
Jin, Tong, Fan (CR13) 2002; 21
Plas, Thompson (CR24) 2003; 278
Liu, Ao, Ding (CR18) 2018; 17
Tran, Brunet, Grenier (CR32) 2002; 296
Park, Miller, Jun (CR23) 2018; 198
Zhan, Antinore, Wang (CR37) 1999; 18
Hollander, Sheikh, Bulavin (CR9) 1999; 23
Ao, Reichel, Hu (CR1) 2015; 355
Ren, Xia, Huang (CR25) 2019; 20
Salvador, Brown-Clay, Fornace, Liebermann, Hoffman (CR26) 2013
Li, Ho, Piperdi (CR15) 2010; 68
Liebermann, Hoffman (CR16) 2008; 3
SQ Jin (399_CR12) 2000; 275
SQ Jin (399_CR13) 2002; 21
K Yao (399_CR36) 2018; 19
M Takekawa (399_CR30) 1998; 95
L Ao (399_CR1) 2015; 355
Y Liu (399_CR18) 2018; 17
J Hildesheim (399_CR8) 2004; 23
TH Li (399_CR15) 2010; 68
ML Smith (399_CR29) 1994; 266
EE Manasanch (399_CR19) 2017; 14
QM Zhan (399_CR37) 1999; 18
F Morgillo (399_CR21) 2011; 71
LQ Liu (399_CR17) 2018; 233
T Tong (399_CR31) 2005; 25
MC Hollander (399_CR9) 1999; 23
GN da Silva (399_CR5) 2018; 24
RL Siegel (399_CR28) 2018; 68
C Bouchard (399_CR3) 2004; 23
J Ji (399_CR11) 2007; 26
KD Miller (399_CR20) 2016; 66
M Gao (399_CR6) 2013; 41
AF Baker (399_CR2) 2014; 33
Q Li (399_CR14) 2018; 9
DR Plas (399_CR24) 2003; 278
WB Ren (399_CR25) 2019; 20
DS Siegel (399_CR27) 2012; 120
H Tran (399_CR32) 2002; 296
AJ van der Wekken (399_CR33) 2016; 100
RZ Orlowski (399_CR22) 2008; 14
F Yang (399_CR35) 2013; 288
JE Park (399_CR23) 2018; 198
C Yang (399_CR34) 2009; 14
HK Chung (399_CR4) 2003; 278
JM Salvador (399_CR26) 2013
NT Hanke (399_CR7) 2016; 142
DA Liebermann (399_CR16) 2008; 3
MC Hollander (399_CR10) 2001; 61
References_xml – volume: 14
  start-page: 124
  issue: 1
  year: 2009
  end-page: 133
  ident: CR34
  article-title: Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45α expression
  publication-title: Apoptosis
  doi: 10.1007/s10495-008-0282-x
  contributor:
    fullname: Wood
– volume: 23
  start-page: 1829
  issue: 10
  year: 2004
  end-page: 1837
  ident: CR8
  article-title: Gadd45a regulates matrix metalloproteinases by suppressing ΔNp63α and -catenin via p38 MAP kinase and APC complex activation
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207301
  contributor:
    fullname: Tyner
– volume: 275
  start-page: 16602
  issue: 22
  year: 2000
  end-page: 16608
  ident: CR12
  article-title: The inhibition of Cdc2 kinase correlates with -mediated growth suppression
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M000284200
  contributor:
    fullname: Lung
– volume: 25
  start-page: 4488
  issue: 11
  year: 2005
  end-page: 4500
  ident: CR31
  article-title: Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.11.4488-4500.2005
  contributor:
    fullname: Jin
– volume: 266
  start-page: 1376
  issue: 5189
  year: 1994
  end-page: 1380
  ident: CR29
  article-title: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
  publication-title: Science
  doi: 10.1126/science.7973727
  contributor:
    fullname: Zhan
– volume: 296
  start-page: 530
  issue: 5567
  year: 2002
  end-page: 534
  ident: CR32
  article-title: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein
  publication-title: Science
  doi: 10.1126/science.1068712
  contributor:
    fullname: Grenier
– volume: 61
  start-page: 2487
  issue: 6
  year: 2001
  end-page: 2491
  ident: CR10
  article-title: Dimethylbenzanthracene carcinogenesis in -null mice is associated with decreased DNA repair and increased mutation frequency
  publication-title: Cancer Res
  contributor:
    fullname: Salvador
– volume: 23
  start-page: 176
  issue: 2
  year: 1999
  end-page: 184
  ident: CR9
  article-title: Genomic instability in -deficient mice
  publication-title: Nat Genet
  doi: 10.1038/13802
  contributor:
    fullname: Bulavin
– start-page: 1
  year: 2013
  end-page: 19
  ident: CR26
  article-title: Gadd45 in stress signaling, cell cycle control, and apoptosis
  publication-title: Gadd45 Stress Sensor Genes
  contributor:
    fullname: Hoffman
– volume: 233
  start-page: 7424
  issue: 9
  year: 2018
  end-page: 7434
  ident: CR17
  article-title: Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.26588
  contributor:
    fullname: Xiong
– volume: 33
  start-page: 111
  year: 2014
  ident: CR2
  article-title: Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-014-0111-8
  contributor:
    fullname: Sands
– volume: 23
  start-page: 2830
  issue: 14
  year: 2004
  end-page: 2840
  ident: CR3
  article-title: Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7600279
  contributor:
    fullname: Brás
– volume: 41
  start-page: 5210
  issue: 10
  year: 2013
  end-page: 5222
  ident: CR6
  article-title: Ribosomal protein S7 regulates arsenite-induced GADD45α expression by attenuating MDM2-mediated GADD45α ubiquitination and degradation
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt223
  contributor:
    fullname: Dong
– volume: 26
  start-page: 6396
  issue: 44
  year: 2007
  end-page: 6405
  ident: CR11
  article-title: Gadd45a regulates -catenin distribution and maintains cell-cell adhesion/contact
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210469
  contributor:
    fullname: Tong
– volume: 95
  start-page: 521
  issue: 4
  year: 1998
  end-page: 530
  ident: CR30
  article-title: A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81619-0
  contributor:
    fullname: Saito
– volume: 18
  start-page: 2892
  issue: 18
  year: 1999
  end-page: 2900
  ident: CR37
  article-title: Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1202667
  contributor:
    fullname: Wang
– volume: 68
  start-page: 89
  issue: 1
  year: 2010
  end-page: 93
  ident: CR15
  article-title: Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC)
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2009.05.009
  contributor:
    fullname: Piperdi
– volume: 17
  start-page: 104
  year: 2018
  ident: CR18
  article-title: Critical role of FOXO3a in carcinogenesis
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0856-3
  contributor:
    fullname: Ding
– volume: 3
  start-page: 15
  year: 2008
  ident: CR16
  article-title: Gadd45 in stress signaling
  publication-title: J Mol Signal
  doi: 10.1186/1750-2187-3-15
  contributor:
    fullname: Hoffman
– volume: 198
  start-page: 1
  year: 2018
  end-page: 16
  ident: CR23
  article-title: Next-generation proteasome inhibitors for cancer therapy
  publication-title: Transl Res
  doi: 10.1016/j.trsl.2018.03.002
  contributor:
    fullname: Jun
– volume: 21
  start-page: 8696
  issue: 57
  year: 2002
  end-page: 8704
  ident: CR13
  article-title: GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206034
  contributor:
    fullname: Fan
– volume: 19
  start-page: 415
  issue: 6
  year: 2018
  end-page: 424
  ident: CR36
  article-title: PGC-1α coordinates with Bcl-2 to control the cell cycle in U251 cells through reducing ROS
  publication-title: J Zhejiang Univ-Sci B (Biomed & Biotechnol)
  doi: 10.1631/jzus.B1700148
  contributor:
    fullname: Du
– volume: 120
  start-page: 2817
  issue: 14
  year: 2012
  end-page: 2825
  ident: CR27
  article-title: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2012-05-425934
  contributor:
    fullname: Wang
– volume: 288
  start-page: 6552
  issue: 9
  year: 2013
  end-page: 6560
  ident: CR35
  article-title: Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.418335
  contributor:
    fullname: Li
– volume: 142
  start-page: 549
  issue: 3
  year: 2016
  end-page: 560
  ident: CR7
  article-title: Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-015-2047-6
  contributor:
    fullname: Baker
– volume: 68
  start-page: 7
  issue: 1
  year: 2018
  end-page: 30
  ident: CR28
  article-title: Cancer statistics, 2018
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
  contributor:
    fullname: Jemal
– volume: 9
  start-page: 524
  issue: 5
  year: 2018
  ident: CR14
  article-title: GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic ape1 level
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-0452-x
  contributor:
    fullname: Zhou
– volume: 14
  start-page: 1649
  issue: 6
  year: 2008
  end-page: 1657
  ident: CR22
  article-title: Proteasome inhibitors in cancer therapy: lessons from the first decade
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-2218
  contributor:
    fullname: Kuhn
– volume: 20
  start-page: 39
  issue: 1
  year: 2019
  end-page: 48
  ident: CR25
  article-title: Interferon-γ regulates cell malignant growth via the c-Abl/HDAC2 signaling pathway in mammary epithelial cells
  publication-title: J Zhejiang Univ-Sci B (Biomed & Biotechnol)
  doi: 10.1631/jzus.B1800211
  contributor:
    fullname: Huang
– volume: 278
  start-page: 12361
  issue: 14
  year: 2003
  end-page: 12366
  ident: CR24
  article-title: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M213069200
  contributor:
    fullname: Thompson
– volume: 278
  start-page: 28079
  issue: 30
  year: 2003
  end-page: 28088
  ident: CR4
  article-title: CR6-interacting factor 1 interacts with Gadd45 family proteins and modulates the cell cycle
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M212835200
  contributor:
    fullname: Jung
– volume: 355
  start-page: 168
  issue: 2
  year: 2015
  end-page: 173
  ident: CR1
  article-title: Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.226993
  contributor:
    fullname: Hu
– volume: 14
  start-page: 417
  issue: 7
  year: 2017
  end-page: 433
  ident: CR19
  article-title: Proteasome inhibitors in cancer therapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.206
  contributor:
    fullname: Orlowski
– volume: 66
  start-page: 271
  issue: 4
  year: 2016
  end-page: 289
  ident: CR20
  article-title: Cancer treatment and survivorship statistics, 2016
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21349
  contributor:
    fullname: Lin
– volume: 71
  start-page: 283
  issue: 3
  year: 2011
  end-page: 290
  ident: CR21
  article-title: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2010.06.005
  contributor:
    fullname: Troiani
– volume: 24
  start-page: 407
  issue: 2
  year: 2018
  end-page: 417
  ident: CR5
  article-title: Gemcitabine/cisplatin treatment induces concomitant and modulation and cellular changes in bladder cancer cells regardless of the site of mutation
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-017-0255-x
  contributor:
    fullname: Salvadori
– volume: 100
  start-page: 107
  year: 2016
  end-page: 116
  ident: CR33
  article-title: Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2016.01.024
  contributor:
    fullname: Hiltermann
– volume: 278
  start-page: 12361
  issue: 14
  year: 2003
  ident: 399_CR24
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M213069200
  contributor:
    fullname: DR Plas
– volume: 233
  start-page: 7424
  issue: 9
  year: 2018
  ident: 399_CR17
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.26588
  contributor:
    fullname: LQ Liu
– volume: 25
  start-page: 4488
  issue: 11
  year: 2005
  ident: 399_CR31
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.25.11.4488-4500.2005
  contributor:
    fullname: T Tong
– volume: 71
  start-page: 283
  issue: 3
  year: 2011
  ident: 399_CR21
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2010.06.005
  contributor:
    fullname: F Morgillo
– volume: 288
  start-page: 6552
  issue: 9
  year: 2013
  ident: 399_CR35
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.418335
  contributor:
    fullname: F Yang
– volume: 296
  start-page: 530
  issue: 5567
  year: 2002
  ident: 399_CR32
  publication-title: Science
  doi: 10.1126/science.1068712
  contributor:
    fullname: H Tran
– volume: 355
  start-page: 168
  issue: 2
  year: 2015
  ident: 399_CR1
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.226993
  contributor:
    fullname: L Ao
– volume: 275
  start-page: 16602
  issue: 22
  year: 2000
  ident: 399_CR12
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M000284200
  contributor:
    fullname: SQ Jin
– volume: 19
  start-page: 415
  issue: 6
  year: 2018
  ident: 399_CR36
  publication-title: J Zhejiang Univ-Sci B (Biomed & Biotechnol)
  doi: 10.1631/jzus.B1700148
  contributor:
    fullname: K Yao
– volume: 18
  start-page: 2892
  issue: 18
  year: 1999
  ident: 399_CR37
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1202667
  contributor:
    fullname: QM Zhan
– volume: 100
  start-page: 107
  year: 2016
  ident: 399_CR33
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2016.01.024
  contributor:
    fullname: AJ van der Wekken
– volume: 68
  start-page: 7
  issue: 1
  year: 2018
  ident: 399_CR28
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21442
  contributor:
    fullname: RL Siegel
– volume: 14
  start-page: 417
  issue: 7
  year: 2017
  ident: 399_CR19
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.206
  contributor:
    fullname: EE Manasanch
– volume: 14
  start-page: 124
  issue: 1
  year: 2009
  ident: 399_CR34
  publication-title: Apoptosis
  doi: 10.1007/s10495-008-0282-x
  contributor:
    fullname: C Yang
– volume: 41
  start-page: 5210
  issue: 10
  year: 2013
  ident: 399_CR6
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt223
  contributor:
    fullname: M Gao
– volume: 33
  start-page: 111
  year: 2014
  ident: 399_CR2
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-014-0111-8
  contributor:
    fullname: AF Baker
– volume: 9
  start-page: 524
  issue: 5
  year: 2018
  ident: 399_CR14
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-0452-x
  contributor:
    fullname: Q Li
– volume: 278
  start-page: 28079
  issue: 30
  year: 2003
  ident: 399_CR4
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M212835200
  contributor:
    fullname: HK Chung
– volume: 266
  start-page: 1376
  issue: 5189
  year: 1994
  ident: 399_CR29
  publication-title: Science
  doi: 10.1126/science.7973727
  contributor:
    fullname: ML Smith
– volume: 68
  start-page: 89
  issue: 1
  year: 2010
  ident: 399_CR15
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2009.05.009
  contributor:
    fullname: TH Li
– volume: 198
  start-page: 1
  year: 2018
  ident: 399_CR23
  publication-title: Transl Res
  doi: 10.1016/j.trsl.2018.03.002
  contributor:
    fullname: JE Park
– volume: 142
  start-page: 549
  issue: 3
  year: 2016
  ident: 399_CR7
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-015-2047-6
  contributor:
    fullname: NT Hanke
– volume: 23
  start-page: 1829
  issue: 10
  year: 2004
  ident: 399_CR8
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207301
  contributor:
    fullname: J Hildesheim
– volume: 23
  start-page: 2830
  issue: 14
  year: 2004
  ident: 399_CR3
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7600279
  contributor:
    fullname: C Bouchard
– volume: 24
  start-page: 407
  issue: 2
  year: 2018
  ident: 399_CR5
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-017-0255-x
  contributor:
    fullname: GN da Silva
– volume: 17
  start-page: 104
  year: 2018
  ident: 399_CR18
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0856-3
  contributor:
    fullname: Y Liu
– volume: 120
  start-page: 2817
  issue: 14
  year: 2012
  ident: 399_CR27
  publication-title: Blood
  doi: 10.1182/blood-2012-05-425934
  contributor:
    fullname: DS Siegel
– volume: 14
  start-page: 1649
  issue: 6
  year: 2008
  ident: 399_CR22
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-2218
  contributor:
    fullname: RZ Orlowski
– volume: 61
  start-page: 2487
  issue: 6
  year: 2001
  ident: 399_CR10
  publication-title: Cancer Res
  contributor:
    fullname: MC Hollander
– volume: 21
  start-page: 8696
  issue: 57
  year: 2002
  ident: 399_CR13
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206034
  contributor:
    fullname: SQ Jin
– volume: 95
  start-page: 521
  issue: 4
  year: 1998
  ident: 399_CR30
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81619-0
  contributor:
    fullname: M Takekawa
– start-page: 1
  volume-title: Gadd45 Stress Sensor Genes
  year: 2013
  ident: 399_CR26
  doi: 10.1007/978-1-4614-8289-5_1
  contributor:
    fullname: JM Salvador
– volume: 23
  start-page: 176
  issue: 2
  year: 1999
  ident: 399_CR9
  publication-title: Nat Genet
  doi: 10.1038/13802
  contributor:
    fullname: MC Hollander
– volume: 20
  start-page: 39
  issue: 1
  year: 2019
  ident: 399_CR25
  publication-title: J Zhejiang Univ-Sci B (Biomed & Biotechnol)
  doi: 10.1631/jzus.B1800211
  contributor:
    fullname: WB Ren
– volume: 66
  start-page: 271
  issue: 4
  year: 2016
  ident: 399_CR20
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21349
  contributor:
    fullname: KD Miller
– volume: 26
  start-page: 6396
  issue: 44
  year: 2007
  ident: 399_CR11
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210469
  contributor:
    fullname: J Ji
– volume: 3
  start-page: 15
  year: 2008
  ident: 399_CR16
  publication-title: J Mol Signal
  doi: 10.1186/1750-2187-3-15
  contributor:
    fullname: DA Liebermann
SSID ssj0044076
Score 2.2705941
Snippet Proteasome inhibitors have shown remarkable success in the treatment of hematologic neoplasm. There has been a lot of attention to applying these drugs for...
SourceID pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 64
SubjectTerms Adenocarcinoma
AKT protein
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cell cycle
Cell growth
Cell proliferation
Cytotoxicity
Environmental stress
Flow cytometry
FOXO3 protein
Gadd45A protein
Gene expression
Inhibitors
Kinases
Lung cancer
Lungs
Neoplasia
Proteasome inhibitors
Solid tumors
Targeted cancer therapy
Toxicity
Tumors
Up-regulation
SummonAdditionalLinks – databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6hrZC40PJOKchICE5Z4meSY6n6EAi4UKkcUGQ7Dhtok2o3Qe3--o7z2GpZDj1n5MQez_j74nkAvM1ZZJVkRWgRPYSiMCJMjVShSqRhwtLCRj7B-ctXdXIqPp3Js1ui2AW7jzeSnaP2Vq04_fB72S6mH_H4iqTPmN6SviP1BLb2j398Phx9r0B60uUTqZiHVCZ0qKq5McD6KbQBLTcjJP-5Ju1On6Nt-Dbm8PRBJ3-mbWOmdrlZ0vGOE9uBhwMQJfv9znkE91z1GO73rSmvn8DPAz0vyvNlfVEaUlaz0pTNgiBaJL-QuDczUhfkHB0F0ei48Dyc27KqLzT5W2rSXs77Dveocy93jN5NSE3c1RB1Wz2F06PD7wcn4dCKIbRCiia0irlYOpmjgedOS55yWqjCKCOjPNaacoW8j1NuY8kcVUZoZrlV2nGWJoXmz2BS1ZV7AYQJRxH14QCILESqTB53ZdOEZTlyzTSAd6Nqssu-4kbmmQquVebXKhvXKoC9UXHZYHiLjPlEWUSRSRTAm9VjNBl_D6IrV7dehnPlCwMmATzv9bx6E7q4NBGCBxCv7YCVgC_Hvf6kKmddWW6VKqSPMoD3o55vP-u_E9i9s-RLeMA8z-9-_ezBpJm37hWCoca8HizgBgEBBuA
  priority: 102
  providerName: Springer Nature
Title Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression
URI https://link.springer.com/article/10.1631/jzus.B1900551
https://www.ncbi.nlm.nih.gov/pubmed/31898443
https://www.proquest.com/docview/2343285180/abstract/
https://search.proquest.com/docview/2333607938
https://pubmed.ncbi.nlm.nih.gov/PMC6964995
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEB7tLgLtBS3vwFIZCcEpbeJXkmO32odAizhQaTmgyHacbVCbVG2KYH894zyKursnLrnYip2Zsef74pkxwPuMBkYKmvsG0YPPc839RAvpy1hoyk2Ym8AlOF9-kRdT_ulKXO2B6HNhmqB9o4thOV8My2LWxFYuF2bUx4mNvl5OZCIRqIvRPuxHjPUUvd1-OTKUJqVIRswPRRx2hTUlC0c_bzbr4Qm6wABxwiE8QntOYs7Zrk-6AzTvxkveOjRtfNHZETzuQCQZt5N9Anu2fAoP22sl_zyDHxO1yov5TbUoNCnKWaGLek0Q6ZFrJN31jFQ5meMiJwo3HfRlK1OU1UKRX4Uim-WqvZ0e9eX6nePOxIUi9ncXMVs-h-nZ6bfJhd9do-AbLnjtG0ltJKzIcHFmVgmWsDCXuZZaBFmkVMgkcjYWMhMJakOpuaKGGakso0mcK_YCDsqqtK-AUG5DRGz4AkQFPJE6i5qSZ9zQDHli4sGHXpDpsq2WkTqWgcJPnfDTXvgeHPdiTrtFs06pS3JFBBgHHrzbNqO5uzMMVdpq4_owJl1Rv9iDl61WtiP16vQg2tHXtoMrpb3bghbWlNTuLMqDj71m_03r3g94_d9jvIFD6jh78xvnGA7q1ca-RWBT6wE8GJ9__3w6cO5FDBqzxueUjv8CaN_7Mw
link.rule.ids 230,315,733,786,790,891,27957,27958,41116,41558,42185,42627,52146,52269,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VIqAXnqUYCiwSgpOdeF-2jxBRAjQVhxb1gqzd9ZqYJnaU2Ajy6xm_gtJygfOuvF598_hmd2YW4GVCh0YKmroG2YPLU83dSAvpylBoyo2fmmFd4Dw5keMz_vFcnO-A6GthmqR9ozMvn829PJs2uZWLuRn0eWKDz5ORjCQSdTG4BtdRX2nQB-mtAeYYozRFRTJgri9Cv2utKZk_-L6uVt5bdIJDZAp7cBMlOgo5Z9te6QrVvJoxeenatPFGR3fgS7-PNgnlwqtK7Zn1pRaP_7zRu3C746fkTTt8D3Zsfh9utC9W_noAX0dqmWazdTHPNMnyaaazckWQRJJvGM-XU1KkZIb2gyi0Z-gmlybLi7kiPzJFqsWyffgeRaGe9x6NHheK2J9dMm6-D2dH705HY7d7ocE1XPDSNZLaQFiRoN4nVgkWMT-VqZZaDJNAKZ9JDAeZz0wgqPWl5ooaZqSyjEZhqthD2M2L3D4CQrn1kQziB5Bw8EjqJGi6qXFDEwxBIwde9QjFi7YRR1wHMIhqXKMa96g6cNjjF3f6uIppXT-L5DIcOvBiM4yaVF-PqNwWVT2HMVn3CwwdOGjh3qzUy4kDwZYgbCbUXbq3RxDTplt3h6EDr3uR-fNbf93A4_9e4zncGp9OjuPjDyefnsAerY8GmtOiQ9gtl5V9ivyp1M8abfkNLI4Z5w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5BEVVfuI9AASMheMrlK8kjLCzlaNUHKlVIKLIdpxvYTVa7WQT765lcC9vy1Gdbcaxvjm_s8QzAi4wGRgqauwbZg8tzzd1EC-nKWGjKTZiboHngfHgkD074x1Nx-k-rrzZp3-jCK6czrywmbW7lfGb8IU_MPz4cyUQiURf-PMv9q3ANdZYmQ6DeGWGOcUr7sEhGzA1FHPblNSUL_e_r1dJ7g44wQLawB7so1UnMOdv2TBfo5sWsyXNXp61HGt-Er8NeukSUH96q1p5ZnyvzeKnN3oIbPU8lr7spt-GKLe_A9a5z5e-78G2kFnkxXVezQpOinBS6qJcEySQ5w7i-npAqJ1O0I0ShXUN3uTBFWc0U-Vkospov7FnfNayZ9x6NHxeK2F99Um55D07G776MDty-U4NruOC1ayS1kbAiQ_3PrBIsYWEucy21CLJIqZBJDAtZyEwkqA2l5ooaZqSyjCZxrth92Cmr0j4EQrkNkRTiB5B48ETqLGqrqnFDMwxFEwdeDiil864gR9oEMohs2iCbDsg6sD9gmPZ6uUxp844WSWYcOPB8M4wa1VyTqNJWq2YOY7KpGxg78KCDfLPSICsORFvCsJnQVOveHkFc26rdPY4OvBrE5u9v_XcDjy69xjPYPX47Tj9_OPr0GPZoc0LQHhrtw069WNknSKNq_bRVmD8C2hxn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Carfilzomib+inhibits+the+growth+of+lung+adenocarcinoma+via+upregulation+of+Gadd45a+expression&rft.jtitle=Journal+of+Zhejiang+University.+B.+Science&rft.au=Yang%2C+Fang&rft.au=Wang-wang%2C+Liu&rft.au=Chen%2C+Hui&rft.au=Zhu%2C+Jia&rft.date=2020-01-01&rft.pub=Springer+Nature+B.V&rft.issn=1673-1581&rft.eissn=1862-1783&rft.volume=21&rft.issue=1&rft.spage=64&rft.epage=76&rft_id=info:doi/10.1631%2Fjzus.B1900551&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1673-1581&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1673-1581&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1673-1581&client=summon